The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    South Korea speeds up full-fledged deployment of US anti-missile battery

  • 3

    Kakao seeks to bolster SM's global presence as new owner

  • 5

    ANALYSISTesla, BYD's price cuts unnerve LGES, Samsung, SK

  • 7

    4 young Nigerian siblings killed in house fire in Ansan

  • 9

    Apple Pay service limited by lack of NFC terminals

  • 11

    SK chief's estranged wife sues his new partner for compensation

  • 13

    Busan aims to win hearts of developing nations in Expo 2030 bid

  • 15

    Bank failures and rescue test Yellen's decades of experience

  • 17

    From mines to mobility: 140-year-old partnership between Germany and Korea

  • 19

    Unrest on the Island of World Peace in 1903

  • 2

    Lee Sun-kyun, Lee Ha-nee reunite in new rom-com 'Killing Romance'

  • 4

    INTERVIEWHow ATEEZ achieved worldwide success

  • 6

    Actor Yoo Ah-in appears for questioning over alleged drug use

  • 8

    Firstborns account for record-high 63% of newborns

  • 10

    Foreign minister hosts Iftar dinner for Muslims in Korea

  • 12

    Chun Doo-hwan's grandson to apologize to victims of Gwangju massacre

  • 14

    Korean police search for 2 Kazakhstanis who fled airport

  • 16

    Samsung chief inspects production plants in China for first time in 3 years

  • 18

    Yoo Ah-in appears before police over alleged use of illegal drugs

  • 20

    Cook praises China's innovation, long history of cooperation on China visit

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Tue, March 28, 2023 | 12:00
Business
Celltrion ships biosimilar medicine to US
Posted : 2016-08-19 19:07
Updated : 2016-08-19 19:56
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
By Kim Tae-gyu

Celltrion CEO Kim Hyoung-ki
Celltrion CEO Kim Hyoung-ki
Korean pharmaceutical firm Celltrion shipped the first batch of its biosimilar medicine Remsima to the U.S. Friday, a day after winning a U.S. lawsuit on sales of the autoimmune disorder drug.

Celltrion said that the move will accelerate the U.S. launch of Remsima, a biosimilar version of Janssen's Remicade. Remsima was put on sale in Europe in 2013.

Pfizer will take charge of sales of Remsima in the U.S., which will soon be available to U.S. patients suffering from rheumatoid arthritis and ulcerative colitis under the brand name of Inflectra in the world's largest pharmaceutical market.

"There remain more procedures before the biosimilar medicine actually hits the U.S. market. Pfizer will put forth efforts to deal with them although we will keep cooperating," a Celltrion official said.

"We believe that our victory in the patent suit cleared the biggest hurdle, which prompted us to start shipment."

Seeking a preliminary injunction to prevent Celltrion from selling Remsima, Janssen filed a complaint in June, two months after the drug received approval from the Federal Drug Administration (FDA).

But the district court ruled against Janssen this week and the firm plans to appeal the decision to an upper court. Yet, Celltrion said that the verdict would not be overturned.

"That's why we are starting to send our products to the U.S. We will put forth efforts to speed up all the necessary procedures," the official said.

Celltrion expects that the U.S. debut of Remsima will boost the company's bottom line as the U.S. autoimmune disease medicine market is estimated to be bigger than $17 billion a year.

Its original drug Remicade, which was developed by Janssen in 1998, had sales of $4.5 billion in the U.S. and $9.9 billion worldwide last year, making it one of the world's most profitable blockbuster medicines.

In a press conference this April, Celltrion CEO Kim Hyoung-ki projected that the company will earn more than $1.7 billion in the U.S. next year, assuming a double-digit market share.

The CEO said at the press conference that the biosimilar medicine will be on the shelf "in the fourth quarter of this year."

In Europe, the firm said that Remsima accounts for more than 30 percent of the market and the proportion would increase to somewhere between 40 percent and 50 percent.

"Based on the trust of European physicians and patients, we expect that penetration into the U.S. market will take place at a much faster pace," the company said in a statement.

Emailvoc200@koreatimes.co.kr Article ListMore articles by this reporter
 
Top 10 Stories
1[ANALYSIS] Tesla, BYD's price cuts unnerve LGES, Samsung, SK ANALYSISTesla, BYD's price cuts unnerve LGES, Samsung, SK
2Yoo Ah-in appears before police over alleged use of illegal drugs Yoo Ah-in appears before police over alleged use of illegal drugs
3US aircraft carrier to visit Busan amid NK provocationsUS aircraft carrier to visit Busan amid NK provocations
4Korean crypto investors want Do Kwon punished in US Korean crypto investors want Do Kwon punished in US
5Families of foreign construction workers can receive retirement pay: court Families of foreign construction workers can receive retirement pay: court
6Indonesian investment minister promotes EV cooperation with Korea Indonesian investment minister promotes EV cooperation with Korea
7Nongshim plans to build plant in eastern US region Nongshim plans to build plant in eastern US region
8Gimpo-China flights recover to pre-pandemic levels Gimpo-China flights recover to pre-pandemic levels
9Right-wing Japanese support Seoul-Tokyo ties: Korean envoy to Japan Right-wing Japanese support Seoul-Tokyo ties: Korean envoy to Japan
10Local bank stocks hit by shockwaves from SVB, CS collapses Local bank stocks hit by shockwaves from SVB, CS collapses
Top 5 Entertainment News
1Lee Sun-kyun, Lee Ha-nee reunite in new rom-com 'Killing Romance' Lee Sun-kyun, Lee Ha-nee reunite in new rom-com 'Killing Romance'
2[INTERVIEW] How ATEEZ achieved worldwide success INTERVIEWHow ATEEZ achieved worldwide success
3Will April releases revive Korean cinema? Films to look out for in April Will April releases revive Korean cinema? Films to look out for in April
4Dreams come true: TXT mesmerizes 21,000 fans at KSPO Dome Dreams come true: TXT mesmerizes 21,000 fans at KSPO Dome
5'My ID is Gangnam Beauty' to be adapted into live action series in Thailand 'My ID is Gangnam Beauty' to be adapted into live action series in Thailand
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group